Generic Loestrin Fe 1/20 Availability

See also: Generic Loestrin 21 1.5/30, Generic Loestrin 21 1/20, Generic Loestrin 24 Fe, Generic Loestrin Fe 1.5/30

Loestrin Fe 1/20 is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):

LOESTRIN FE 1/20 (ethinyl estradiol; norethindrone acetate - tablet;oral-28)

  • Manufacturer: WARNER CHILCOTT
    Approved Prior to Jan 1, 1982
    Strength(s): 0.02MG;1MG [AB]

Has a generic version of Loestrin Fe 1/20 been approved?

Yes. The following products are equivalent to Loestrin Fe 1/20:

GILDESS FE 1/20 (ethinyl estradiol; norethindrone acetate tablet;oral-28)

  • Manufacturer: VINTAGE PHARMS LLC
    Approval date: May 20, 2005
    Strength(s): 0.02MG;1MG [AB]

JUNEL FE 1/20 (ethinyl estradiol; norethindrone acetate tablet;oral-28)

  • Manufacturer: BARR
    Approval date: September 18, 2003
    Strength(s): 0.02MG;1MG [AB]

LARIN FE 1/20 (ethinyl estradiol; norethindrone acetate tablet;oral-28)

  • Manufacturer: NOVAST LABS LTD
    Approval date: August 26, 2013
    Strength(s): 0.02MG;1MG [AB]

MICROGESTIN FE 1/20 (ethinyl estradiol; norethindrone acetate tablet;oral-28)

  • Manufacturer: WATSON LABS
    Approval date: February 5, 2001
    Strength(s): 0.02MG;1MG [AB]

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL (ethinyl estradiol; norethindrone acetate tablet;oral-28)

  • Manufacturer: FAMY CARE LTD
    Approval date: November 14, 2013
    Strength(s): 0.02MG;1MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Loestrin Fe 1/20. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Loestrin Fe 1/20.

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web3)